

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein said NSAID is intrathecally delivered.

2. (Cancelled)

3. (Cancelled)

4. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

5. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

6. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

7. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

8. (Withdrawn) A method of treating diffuse axonal injury, said method comprising administering to a subject having diffuse axonal injury a therapeutically effective amount of a naturally occurring omega conotoxin, a functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.

9. (Withdrawn) A method according to claim 8, wherein the naturally occurring omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof is an N-type calcium channel blocker.

10. (Withdrawn) A method according to claim 8, wherein the naturally occurring omega conotoxin is selected from the group consisting essentially of GVIA and MVII.

11. (Withdrawn) A method according to claim 8, wherein said administering step further comprises intrathecally delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

12. (Withdrawn) A method according to claim 8, wherein said administering step further comprises intraventricularly delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.

13. (Withdrawn) A method according to claim 8, wherein said administering step further comprises delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject through an implantable pump.

14. (Withdrawn) A method according to claim 8, wherein said administering step further comprises delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject through a spinal catheter.

15. (Withdrawn) A method according to claim 8, wherein the diffuse axonal injury is a spastic disorder.

16. (Withdrawn) A method according to claim 15, wherein the spastic disorder is caused by traumatic brain injury.

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

17. (Withdrawn) A method according to claim 8 further including the step of administering a non-steroidal anti-inflammatory drug to the subject.

18. (Withdrawn) A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

19. (Withdrawn) A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

20. (Withdrawn) A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

21. (Withdrawn) A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

22. (Withdrawn) A method for treating pain, said method comprising administering to a subject having pain a therapeutically effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

23. (Withdrawn) A method according to claim 22, wherein the NSAID is intrathecally delivered.

24. (Withdrawn) A method according to claim 22, wherein the NSAID is intraventricularly delivered.

25. (Withdrawn) A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

26. (Withdrawn) A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

27. (Withdrawn) A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

28. (Withdrawn) A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

29. (Currently Amended) A method for treating neuronal injury said method comprising intrathecally administering to a subject having neuronal injury a therapeutically

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, ~~derivative~~, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

30. (Original) A method according to claim 29, wherein the NSAID is intraventricularly delivered.

31. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

32. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

33. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

34. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

35. (Original) A method according to claim 29, wherein the neuronal injury is caused by Lupus, inflammatory neuropathy, infection, acquired disorders, transverse myelitis, Parkinson's disease, CNS vasculitis, or Alzheimer's disease.

36. (New) A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein said NSAID is intraventricularly delivered.

37. (New) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

38. (New) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

39. (New) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

Serial No. 10/049,327

Amendment in Reply to Office Action of 10/3/03

40. (New) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

41. (New) A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of choline magnesium trisalicylate, analog, substituted form, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.